| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 110,957.0 | 103,150.0 |
| Gross profit | 3,956.0 | 3,542.0 |
| Net income | 1,218.0 | 1,110.0 |
| EPS (diluted, $ a share) | $10.44 | $8.92 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +9.7% |
|---|---|
| Revenue, year on year | +7.6% |
| Gross margin | 3.6% |
| Operating margin | 1.4% |
10-Q filed with the SEC, NYSE: MCK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Mckesson Corp: key numbers
- Share price
- $1,105.04Close, Nov 16
- Market cap
- $128B
- Shares outstanding
- 115.46MLatest SEC cover page
- Sector
- Trade & Services
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' SundriesSIC 5122
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Mckesson Corp
All →Mckesson EVP, CIO and CTO Francisco Fraga Sells $717K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 650 shares of Mckesson Corp at $1,102.96 a share, worth $717K in total on Nov 5, 2026. Shares held after the trade: 4,414 (-12.8%).
- Value
- $717K
- Shares
- 650
- Price
- $1,102.96
- Role
- EVP, CIO and CTO
- Holding change
- -12.8%
- Trade date
- Nov 5, 2026
McKesson Earnings Call: Key Takeaways
McKesson delivered a strong Q2 FY2027, beating internal expectations and raising full-year EPS guidance, driven by specialty distribution, GLP-1 volume, and strategic acquisitions in oncology and home infusion.
- Call
- Nov 4, 2026, 4:30 PM ET
Mckesson EVP, CIO and CTO Francisco Fraga Sells $630K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 600 shares of Mckesson Corp at $1,050.00 a share, worth $630K in total on Nov 4, 2026. Shares held after the trade: 5,064 (-10.6%).
- Value
- $630K
- Shares
- 600
- Price
- $1,050.00
- Role
- EVP, CIO and CTO
- Holding change
- -10.6%
- Trade date
- Nov 4, 2026
Mckesson Financial Results
McKesson reported second quarter fiscal 2027 consolidated revenues of $111.0 billion, an 8% increase year-over-year, and raised its full-year adjusted EPS guidance. The results were driven by strong operational growth in the North American Pharmaceutical and Oncology & Multispecialty segments.
- Term
- Q2 2027
“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise.”
Brian Tyler, chair and chief executive officer
Mckesson EVP, CIO and CTO Francisco Fraga Sells $797K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 800 shares of Mckesson Corp at $995.80 a share, worth $797K in total on Oct 15, 2026. Shares held after the trade: 5,423 (-12.9%).
- Value
- $797K
- Shares
- 800
- Price
- $995.80
- Role
- EVP, CIO and CTO
- Holding change
- -12.9%
- Trade date
- Oct 15, 2026
Mckesson Signs $5.8B M&A Deal with Option Care Health, Inc.
McKesson Corporation and Clayton, Dubilier & Rice (CD&R) have entered into a definitive agreement to acquire Option Care Health for $32.05 per share, representing a total enterprise value of approximately $5.8 billion. Upon closing, CD&R will hold a majority stake while McKesson will hold a minority interest in the home and alternate site infusion services provider. The deal aligns with McKesson's strategy to expand access to innovative therapies in lower-cost community and home settings.
- Value
- $5.8B
- Counterparty
- Option Care Health, Inc.